JPWO2020210418A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210418A5 JPWO2020210418A5 JP2021559978A JP2021559978A JPWO2020210418A5 JP WO2020210418 A5 JPWO2020210418 A5 JP WO2020210418A5 JP 2021559978 A JP2021559978 A JP 2021559978A JP 2021559978 A JP2021559978 A JP 2021559978A JP WO2020210418 A5 JPWO2020210418 A5 JP WO2020210418A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- pharmaceutical composition
- day
- cycle
- cycles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 16
- 229960004641 rituximab Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229940125904 compound 1 Drugs 0.000 claims 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 5
- 201000003444 follicular lymphoma Diseases 0.000 claims 5
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833432P | 2019-04-12 | 2019-04-12 | |
| US62/833,432 | 2019-04-12 | ||
| PCT/US2020/027358 WO2020210418A1 (en) | 2019-04-12 | 2020-04-09 | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527398A JP2022527398A (ja) | 2022-06-01 |
| JPWO2020210418A5 true JPWO2020210418A5 (es) | 2023-04-17 |
| JP7562557B2 JP7562557B2 (ja) | 2024-10-07 |
Family
ID=70465546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559978A Active JP7562557B2 (ja) | 2019-04-12 | 2020-04-09 | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11390617B2 (es) |
| EP (1) | EP3952880A1 (es) |
| JP (1) | JP7562557B2 (es) |
| KR (1) | KR20210151895A (es) |
| CN (1) | CN114144182B (es) |
| AR (1) | AR119715A1 (es) |
| AU (1) | AU2020270917A1 (es) |
| BR (1) | BR112021020372A2 (es) |
| CA (1) | CA3132538A1 (es) |
| CL (1) | CL2021002651A1 (es) |
| IL (1) | IL287145A (es) |
| MA (1) | MA55608A (es) |
| MX (1) | MX2021012507A (es) |
| SG (1) | SG11202111232RA (es) |
| WO (1) | WO2020210418A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210116454A1 (en) * | 2019-10-21 | 2021-04-22 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| EP4048666A1 (en) * | 2019-10-21 | 2022-08-31 | Celgene Corporation | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use |
| CN114786665A (zh) * | 2019-10-21 | 2022-07-22 | 新基公司 | 取代的4-氨基异二氢吲哚-1,3-二酮化合物和第二种活性剂的组合用途 |
| EP4048279A1 (en) * | 2019-10-21 | 2022-08-31 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| US11666579B2 (en) * | 2019-10-21 | 2023-06-06 | Celgene Corporation | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| US11504378B2 (en) | 2019-10-21 | 2022-11-22 | Celgene Corporation | Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same |
| AU2022252220A1 (en) * | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma |
| BR112023019943A2 (pt) * | 2021-04-21 | 2023-11-14 | Bristol Myers Squibb Co | Métodos de tratamento de linfoma de células b usando terapia combinada |
| BR112023021015A2 (pt) * | 2021-04-21 | 2023-12-19 | Bristol Myers Squibb Co | Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona |
| JP2024522748A (ja) | 2021-06-21 | 2024-06-21 | セルジーン コーポレーション | （ｓ）－２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンの調製のための方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1353672T3 (da) | 2000-11-30 | 2008-01-21 | Childrens Medical Center | Syntese af 4-amino-thalidomidenantiomerer |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| SI3202461T1 (sl) | 2010-02-11 | 2019-05-31 | Celgene Corporation | Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh |
| US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
| JP6347782B2 (ja) | 2012-08-09 | 2018-06-27 | セルジーン コーポレイション | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| SG11201503456TA (en) | 2012-11-05 | 2015-05-28 | Celgene Corp | Treatment of cancer with pomalidomide in a renally impaired subject |
| WO2014165482A1 (en) | 2013-04-02 | 2014-10-09 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| KR102191256B1 (ko) | 2014-10-30 | 2020-12-15 | 강푸 바이오파마슈티칼즈 리미티드 | 이소인돌린 유도체, 이의 중간체, 제조방법, 약물 조성물 및 응용 |
| SG11202000143PA (en) * | 2017-07-10 | 2020-02-27 | Celgene Corp | Antiproliferative compounds and methods of use thereof |
| WO2019209692A1 (en) | 2018-04-23 | 2019-10-31 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
-
2020
- 2020-04-08 AR ARP200101015A patent/AR119715A1/es unknown
- 2020-04-09 KR KR1020217036544A patent/KR20210151895A/ko unknown
- 2020-04-09 MX MX2021012507A patent/MX2021012507A/es unknown
- 2020-04-09 US US16/844,407 patent/US11390617B2/en active Active
- 2020-04-09 EP EP20722180.5A patent/EP3952880A1/en active Pending
- 2020-04-09 CA CA3132538A patent/CA3132538A1/en active Pending
- 2020-04-09 MA MA055608A patent/MA55608A/fr unknown
- 2020-04-09 JP JP2021559978A patent/JP7562557B2/ja active Active
- 2020-04-09 BR BR112021020372A patent/BR112021020372A2/pt unknown
- 2020-04-09 AU AU2020270917A patent/AU2020270917A1/en active Pending
- 2020-04-09 SG SG11202111232RA patent/SG11202111232RA/en unknown
- 2020-04-09 CN CN202080043197.0A patent/CN114144182B/zh active Active
- 2020-04-09 WO PCT/US2020/027358 patent/WO2020210418A1/en unknown
-
2021
- 2021-10-08 CL CL2021002651A patent/CL2021002651A1/es unknown
- 2021-10-10 IL IL287145A patent/IL287145A/en unknown
-
2022
- 2022-06-24 US US17/848,976 patent/US12103923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021155426A5 (es) | ||
| JP2022121594A5 (es) | ||
| JP2019536805A5 (es) | ||
| JP2019503365A5 (es) | ||
| JP2019517587A5 (es) | ||
| JP2020514311A5 (es) | ||
| CN103619330A (zh) | 用于治疗糖尿病的选择性雄激素受体调节剂 | |
| JP2015212268A5 (es) | ||
| JP2011511071A5 (es) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2019516684A5 (es) | ||
| JPWO2020210418A5 (es) | ||
| JP2020524670A5 (es) | ||
| JP2018507243A5 (es) | ||
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| TW201822769A (zh) | 用於治療非小細胞肺癌之egfr t790m 抑制劑及cdk抑制劑之組合 | |
| JP2018090566A5 (es) | ||
| JP2008540528A5 (es) | ||
| JP2009514879A5 (es) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2020523384A5 (es) | ||
| JP2017524652A5 (es) | ||
| JP2022058873A5 (es) | ||
| AT503317B1 (de) | Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen | |
| JP2020536923A5 (es) |